News

News

December 22, 2010

New candidate antibody-drug conjugate gains broad patent coverage

December 14, 2010

UCB announces start of phase III program with Epratuzumab for patients with moderate to severe systematic lupus erythematosus

December 7, 2010

Immunomedics develops new antibody-drug conjugate for hematologic cancer therapy

December 6, 2010

First results from phase II study of fractionated radioimmunotherapy with 90Y Epratuzumab in aggressive lymphoma presented at hematology conference

December 6, 2010

Results from phase II trial of Epratuzumab and Rituximab as initial treatment for follicular lymphoma reported in an oral presentation at ASH

December 5, 2010

Immunomedics reports progress with Milatuzumab at 52nd ASH annual meeting

December 1, 2010

Immunomedics announces outcome of 2010 annual meeting of stockholders

November 11, 2010

Immunomedics’ product candidates to be presented at the 52nd ASH annual meeting

November 9, 2010

Epratuzumab phase IIb data presented at ACR show pipeline drug had positive effect in patients suffering from moderate to severe systematic lupus erythematosus

Novemeber 4, 2010

Immunomedics announces first quarter fiscal 2011 results and clinical program developments

November 2, 2010

Immunomedics awarded 12 qualifying therapeutic discovery project grants

October 28, 2010

Immunomedics to present at upcoming healthcare conferences

October 12, 2010

Immunomedics awarded additional US patent for antibody therapy autoimmune diseases

October 8, 2010

Immunomedics to webcast October 15th R&D Day

September 15, 2010

Immunomedics to present at 2010 UBS Global Life Sciences Conference

August 26, 2010

Immunomedics announces fiscal 2010 results

August 18, 2010

Immunomedics and GE Healthcare in research collaboration

August 10, 2010

Immunomedics awarded additional US patent for internalizing anti-CD74 antibodies and methods of use

June 25, 2010

Epratuzumab data from phase IIb Emblem™ study presented at 9th International Congress on Systematic Lupus Erythematosis

June 21, 2010

Results from randomized study of Epratuzumab in patients with systematic lupus erythematosis presented at European Rheumatology Congress

June 16, 2010

New data from Emblem study show pipeline drug Epratuzumab provided significant efficacy for patients suffering from moderate to severe lupus erythematosus

June 15, 2010

Immunomedics doses first patient in phase I/II study of Milatuzumab-Doxorubicin conjugate for multiple myeloma therapy

June 9, 2010

Immunomedics announces preclinical results of pretargeted imaging and therapy of cancer

June 9, 2010

Immunomedics presents new antibody for pretargeting epithelial cancers at medical conference

June 8, 2010

Immunomedics reports first clinical experience with new generation of bispecific antibody

June 7, 2010

Immunomedics reports updated results of targeted therapy for advanced pancreatic cancer

June 4, 2010

Immunomedics to present at upcoming investor conferences

June 1, 2010

Immunomedics to report progress on cancer imaging and therapy in 9 presentations at the Society of Nuclear Medicine’s 57th annual meeting

May 25, 2010

Immunomedics receives second milestone payment from Nycomed

May 13, 2010

Results from randomized study of Epratuzumab in patients with lupus to be presented at European Rheumatology Congress

May 10, 2010

Immunomedics announces third quarter fiscal 2010 results and clinical program developments

April 21, 2010

Immunomedics develops potent immunotoxins against solid and liquid tumors

April 20, 2010

Immunomedics reports new blood test for detecting early stage pancreatic cancer correlates with response to Clivatuzumab Tetraxetan treamtment

April 19, 2010

Immunomedics reports progress on antibody-drug conjugate development at cancer meeting

April 19, 2010

Immunomedics develops novel immunoconjugate for targeted deliver of siRNAs to solid cancers

April 12, 2010

Immunomedics to report on potential cancer therapy products in 8 presentations at 101st annual AACR meeting

March 15, 2010

Immunomedics to present an Barclays Capital 2010 Global Healthcare Conference

February 23, 2010

Immunomedics awarded patents for antibody pegylation and pretargeting constructs

February 22, 2010

Immunomedics to participate in upcoming conferences

February 17, 2010

Immunomedics awarded patent for antibody therapy

February 10, 2010

Immunomedics appoints Kenneth J. Zuerblis to Board of Directors

February 2, 2010

Immunomedics announces second quarter fiscal 2010 results and clinical program developments

January 25, 2010

New targeted therapy for pancreatic caner presented at cancer conference

January 21, 2010

New blood test for detecting early stage pancreatic cancer presented at cancer conference

January 19, 2010

Immunomedics receives first milestone payment from Nycomed

January 8, 2010

Potential lupus drug gains US patent

January 6, 2010

Immunomedics to present at 28th annual J.P. Morgan Healthcare Conference